logo
logo

Infinimmune Raises $12 Million In Seed Funding To Pioneer Novel Approach To Antibody Drug Discovery And Development

Infinimmune Raises $12 Million In Seed Funding To Pioneer Novel Approach To Antibody Drug Discovery And Development

12/06/22, 1:32 PM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/US.svgalameda
Money raised
$12 million
Industry
therapeutics
biotechnology
health care
Round Type
seed
Investors
Axial Vc, Civilization Ventures, Pear Vc
Infinimmune, a biotechnology company pioneering new methods for antibody drug discovery and development, today announced that it has closed a $12 million seed round led by Playground Global, with participation from Pear VC, Civilization Ventures, Axial VC, Ron Alfa, Jacob Becraft, Paul Conley, and Joshua Meier.

Company Info

Company
Infinimmune
Location
alameda, california, united states
Additional Info
Infinimmune is a biotechnology company pioneering a novel approach to antibody drug discovery and development. Founded by a world-class, multidisciplinary team of scientists and technologists, Infinimmune is reinventing antibody discovery with an end-to-end platform to deliver antibody drugs derived directly from the human immune system. These truly human antibodies are designed to drug new and existing targets with improved safety and efficacy. Infinimmune will deploy its holistic approach to build its own pipeline of drug candidates and partner with pharmaceutical companies to advance their antibody programs, fill their pipelines, and reach new patients and new indications.

Related People